Category: Replacement Heart Valves
Abiomed unveils new results from an IDE study of its Impella Right Percutaneous heart pump, reporting 73% survival in patients with right ventricular failure.
Abiomed (NSDQ:ABMD) got some Wall Street love today after releasing positive outcomes from a clinical trial of its minimally invasive Impella Right Percutaneous heart pump.
Researchers reported an overall 73% 30-day survival rate in the small study of patients with right ventricular heart failure, according to data Abiomed released during the Transcatheter Cardiovascular Therapeutics conference in Washington D.C.
Boston Scientific's Lotus replacement heart valve shows low leakage rates and no instances of moderate or severe leakage, a problem that plagued the earlier generation of transcatheter aortic valve implants.
Transcatheter aortic valve implants take center stage at the annual Transcatheter Cardiovascular Therapeutics conference with the latest data dumps from rivals Medtronic and Edwards Lifesciences.
St. Jude Medical hits 'pause' on implantations of its Portico replacement heart valve after CT scans turned up a potential problem with the devices.
After more than 10 years underground, MVRx unveils its mitral valve repair system during the Transcatheter Cardiovascular Therapeutics conference.
MASSDEVICE ON CALL — Bad timing and a financial crisis nearly buried MVRx and its mitral valve repair technology forever, but the company's founders finally revealed their progress over the weekend at the Transcatheter Cardiovascular Therapeutics conference.
Symetis has been battling Medtronic and Edwards Lifesciences for years in the European transcatheter aortic valve implantation market, and the company's aiming to squeeze out Boston Scientific, St. Jude Medical and other major players in the U.S.
Switzerland-based medical implant maker Symetis is looking to make some major moves in the global transcatheter aortic valve implantation market, and the company's not afraid to take on some of the medtech industry's biggest players.
Symetis Joins Industry Leaders Edwards Lifesciences and Medtronic as Only Companies to Offer Both Transapical and Transfemoral Options for Transcatheter Aortic Heart Valve Delivery
LAUSANNE, SWITZERLAND - Symetis SA, the leading European developer of transcatheter aortic valve implantation (TAVI) systems, announced today the launch of ACURATE neo, its 15F compatible transfemoral TAVI system. Commercial implantations started early September after Symetis received CE Mark approval for ACURATE neo this summer.